Integrative analysis of survival-associated gene sets in breast cancer
暂无分享,去创建一个
Chao Cheng | M. Ung | S. Lou | F. Varn
[1] Chao Cheng,et al. E2F4 regulatory program predicts patient survival prognosis in breast cancer , 2014, Breast Cancer Research.
[2] S. Drăghici,et al. Analysis and correction of crosstalk effects in pathway analysis , 2013, Genome research.
[3] Chun-Chi Liu,et al. REACTIN: Regulatory activity inference of transcription factors underlying human diseases with application to breast cancer , 2013, BMC Genomics.
[4] Stefan Glück,et al. Molecular Profiling for Breast Cancer: A Comprehensive Review , 2013, Biomarkers in cancer.
[5] Marketa Zvelebil,et al. ROCK: a resource for integrative breast cancer data analysis , 2013, Breast Cancer Research and Treatment.
[6] Arnoldo Frigessi,et al. Combining Gene Signatures Improves Prediction of Breast Cancer Survival , 2011, PloS one.
[7] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[8] Y. Qi,et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. , 2011, Journal of the National Cancer Institute.
[9] Mitch Dowsett,et al. Current and emerging biomarkers in breast cancer: prognosis and prediction. , 2010, Endocrine-related cancer.
[10] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Kölbl,et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.
[12] R. Salunga,et al. A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer , 2008, Clinical Cancer Research.
[13] Fengzhu Sun,et al. Inferring activity changes of transcription factors by binding association with sorted expression profiles , 2007, BMC Bioinform..
[14] J. Bergh,et al. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.
[15] I. Ellis,et al. A gene-expression signature to predict survival in breast cancer across independent data sets , 2007, Oncogene.
[16] G. Sherlock,et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.
[17] I. Ellis,et al. A consensus prognostic gene expression classifier for ER positive breast cancer , 2006, Genome Biology.
[18] A. Weeraratna,et al. Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells , 2006, Oncogene.
[19] L. Ein-Dor,et al. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. J. van de Vijver,et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.
[21] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[22] P. Hall,et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[23] G. Glinsky,et al. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. , 2005, The Journal of clinical investigation.
[24] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[26] Stefan Michiels,et al. Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.
[27] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[28] P. Brown,et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[29] Wei Wang,et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.
[30] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[31] Emanuel Petricoin,et al. Molecular profiling of human cancer , 2000, Nature Reviews Genetics.
[32] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[33] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[34] T. Ideker,et al. Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.
[35] 佐治 重衡,et al. What's going on 乳癌 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, et al. Cancer Cell. 2004;5:607-16. PMID:15193263--術後補助療法におけるタモキシフェンへの反応性は2つの遺伝子レベルの測定によって予測しうることを示した論文 , 2005 .
[36] J. Haerting,et al. Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.
[37] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.